source
- Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at riskIonis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…
- Rezolute’s phase 3 trial of ersodetug meets primary endpoint in tumor hyperinsulinismRezolute reported that its phase 3 Uplift study of ersodetug in tumor hyperinsulinism achieved its primary endpoint. The trial required at least nine of 16 patients to show a 50% or greater reduct…